TY - JOUR
T1 - Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial
AU - Grünig, Ekkehard
AU - MacKenzie, Alison
AU - Peacock, Andrew J.
AU - Eichstaedt, Christina A.
AU - Benjamin, Nicola
AU - Nechwatal, Robert
AU - Ulrich, Silvia
AU - Saxer, Stéphanie
AU - Bussotti, Maurizio
AU - Sommaruga, Marinella
AU - Ghio, Stefano
AU - Gumbiene, Lina
AU - Palevičiūtė, Eglė
AU - Jurevičienė, Elena
AU - Cittadini, Antonio
AU - Stanziola, Anna A.
AU - Marra, Alberto M.
AU - Kovacs, Gabor
AU - Olschewski, Horst
AU - Barberà, Joan-Albert
AU - Blanco, Isabel
AU - Spruit, Martijn A.
AU - Franssen, Frits M. E.
AU - Vonk Noordegraaf, Anton
AU - Reis, Abílio
AU - Santos, M. rio
AU - Viamonte, Sofia Gonçalves
AU - Demeyer, Heleen
AU - Delcroix, Marion
AU - Bossone, Eduardo
AU - Johnson, Martin
N1 - Publisher Copyright:
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2021/6/14
Y1 - 2021/6/14
N2 - AIMS: This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). METHODS AND RESULTS: For the first time a specialized PAH/CTEPH rehabilitation programme was implemented in 11 centres across 10 European countries. Out of 129 enrolled patients, 116 patients (58 vs. 58 randomized into a training or usual care control group) on disease-targeted medication completed the study [85 female; mean age 53.6 ± 12.5 years; mean pulmonary arterial pressure 46.6 ± 15.1 mmHg; World Health Organization (WHO) functional class II 53%, III 46%; PAH n = 98; CTEPH n = 18]. Patients of the training group performed a standardized in-hospital rehabilitation with mean duration of 25 days [95% confidence interval (CI) 17-33 days], which was continued at home. The primary endpoint, change of 6-min walking distance, significantly improved by 34.1 ± 8.3 m in the training compared with the control group (95% CI, 18-51 m; P < 0.0001). Exercise training was feasible, safe, and well-tolerated. Secondary endpoints showed improvements in quality of life (short-form health survey 36 mental health 7.3 ± 2.5, P = 0.004), WHO-functional class (training vs. control: improvement 9:1, worsening 4:3; χ2P = 0.027) and peak oxygen consumption (0.9 ± 0.5 mL/min/kg, P = 0.048) compared with the control group. CONCLUSION: This is the first multicentre and so far the largest randomized, controlled study on feasibility, safety, and efficacy of exercise training as add-on to medical therapy in PAH and CTEPH. Within this study, a standardized specialized training programme with in-hospital start was successfully established in 10 European countries.
AB - AIMS: This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). METHODS AND RESULTS: For the first time a specialized PAH/CTEPH rehabilitation programme was implemented in 11 centres across 10 European countries. Out of 129 enrolled patients, 116 patients (58 vs. 58 randomized into a training or usual care control group) on disease-targeted medication completed the study [85 female; mean age 53.6 ± 12.5 years; mean pulmonary arterial pressure 46.6 ± 15.1 mmHg; World Health Organization (WHO) functional class II 53%, III 46%; PAH n = 98; CTEPH n = 18]. Patients of the training group performed a standardized in-hospital rehabilitation with mean duration of 25 days [95% confidence interval (CI) 17-33 days], which was continued at home. The primary endpoint, change of 6-min walking distance, significantly improved by 34.1 ± 8.3 m in the training compared with the control group (95% CI, 18-51 m; P < 0.0001). Exercise training was feasible, safe, and well-tolerated. Secondary endpoints showed improvements in quality of life (short-form health survey 36 mental health 7.3 ± 2.5, P = 0.004), WHO-functional class (training vs. control: improvement 9:1, worsening 4:3; χ2P = 0.027) and peak oxygen consumption (0.9 ± 0.5 mL/min/kg, P = 0.048) compared with the control group. CONCLUSION: This is the first multicentre and so far the largest randomized, controlled study on feasibility, safety, and efficacy of exercise training as add-on to medical therapy in PAH and CTEPH. Within this study, a standardized specialized training programme with in-hospital start was successfully established in 10 European countries.
KW - Exercise programme
KW - Pulmonary hypertension
KW - Pulmonary rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=85101232889&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehaa696
DO - 10.1093/eurheartj/ehaa696
M3 - Article
C2 - 33232470
VL - 42
SP - 2284
EP - 2295
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 23
ER -